Overview

Tercica, Inc. is a biopharmaceutical company focused on the development and commercialization of products to improve endocrine health. The company’s first product, Increlex™, or recombinant human insulin-like growth factor-1 (rhIGF-1) was approved for the long-term treatment of severe Primary IGFD.

View Tercica's 2006 Letter to Stockholders

View Tercica's Safe-Harbor Statement

Shareholder Information Exchange
NASDAQ

Listed Security
TRCA Common Stock

Transfer Agent
Computershare Trust Co., N.A.
P.O. Box 43010
Providence, RI 02940-3010
ph: 781-575-2879
website: www.computershare.com

Return to Top >>